FDA issues draft guidance document, “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act.” The draft guidance addresses early planning for pediatric evaluation of certain molecularly targeted oncology drugs.
Similar Posts
Clinical Outcome Assessment (COA): Frequently Asked Questions
Clinical Outcome Assessments (COA) Frequently Asked QuestionsKoikoi Trading Inc., Issues Allergy Alert on Undeclared Wheat and Sesame in FU ZHOU FISH BALL (200g / 400g / 5lb)
Commerce, CA – Koikoi Trading Inc. is recalling certain lots of FU ZHOU FISH BALL products in multiple pack sizes (200g, 400g, and 5LB) because the products may contain undeclared allergens: wheat and sesame. People who have an allergy or severe sensitivity to wheat and/or sesame run the risk of a sDrug Trials Snapshots: VIZZ
Drug Trials Snapshots: VIZZWhat’s New Related to Drugs
Want to know what’s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.Walgreen Company – 662158 – 09/12/2023
Failure to Register and ListRevitalize Energy, Inc. – 712417 – 07/09/2025
Unapproved New Drugs/Misbranded